

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	<b>Application Number</b>		10647068
	<b>Filing Date</b>		2003-08-22
	<b>First Named Inventor</b>	Argenta, et al.	
	<b>Art Unit</b>	3733	
	<b>Examiner Name</b>	PHILOGENE, PEDRO	
<b>Attorney Docket Number</b>		0101-P02977US1	

U.S. PATENTS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								<a href="#">Remove</a>
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. [Add](#)

NON-PATENT LITERATURE DOCUMENTS		<a href="#">Remove</a>
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Ts

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

1	FLEISCHMANN, W., et al., "Thoracic spinal column, risks, and complications of therapy", OP-Journal, (7 sheets, 11 sheets of translation and 8 sheets of another Translation); 6(3):31-35 (December 1990). NPL-156	<input type="checkbox"/>
2	FLEISCHMANN, W., et al., "Vacuum sealing as treatment of soft tissue injury in open fractures", Unfallchirurg Springer - Verlag, (English abstract on first page, and 8 pages of English translation); 96:488-92, (1993). NPL-157	<input type="checkbox"/>
3	FLEISCHMANN, W., "Vacuum sealing for treatment of problematical wounds", Wund Forum Spezial - IHW, (4 sheets English translation); pp. 54-55 (1994). NPL-160	<input type="checkbox"/>
4	FLEISCHMANN, W., et al., "Vacuum assisted closure of wounds following dermatofasciotomy of the leg", Unfallchirurg., (English abstract on page 284, and 1 sheet printout from PubMed); 99(4):283-7, (April 1996). NPL-161	<input type="checkbox"/>
5	FORD, C.N., et al., "Interim analysis of a prospective, randomized trial of vacuum-assisted closure versus the healthpoint system in the management of pressure ulcers", Ann. Plast. Surg., (11 sheets); 49(1):55-61 (July 2002). NPL-163	<input type="checkbox"/>
6	FOX, R., "A rapid screen for drug abuse", Pharmaceutical J., page 789, (June 18, 1988). NPL-165	<input type="checkbox"/>
7	GOUTTEFANGEAS, C., et al., "Functional T lymphocytes infiltrate implanted polyvinyl alcohol foams during surgical wound closure therapy," Clin. Exp. Immunol., 124(3):398-405 (June 2001). NPL-173	<input type="checkbox"/>
8	GRABOWSKI, S., "Treatment of the wounds in hypotension", Pol. Tyg. Lek., (English abstract on page 21 and 1 sheet printout from PubMed); 19:19-21, (January 1, 1964). NPL-174	<input type="checkbox"/>
9	GREER, S.E., et al., "Subatmospheric pressure dressing for saphenous vein donor-site complications," Ann. Thorac. Surg., (6 sheets); 71(3):1038-40 (March 2001). NPL-176	<input type="checkbox"/>
10	Excerpts "Dead Space", "Wound Closure", "Drainage", "Dressing" and "Epilogue" in "Fundamentals of Wound Management," T K. Hunt and J.E. Dunphy, eds., Appleton-Century Crofts NY pp. 416-447, (1979). NPL-186	<input type="checkbox"/>
11	HAWKINS-BRADLEY, B., et al., "Treatment of a nonhealing wound with hypergranulation tissue and rolled edges", J. Wound Ostomy Continence Nurs., 29(6):320-324 (November 2002). NPL-187	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

12	HARLAN, J.W., "Treatment of open sternal wounds with the vacuum-assisted closure system: a safe, reliable method", <i>Plast. Reconstruct. Surg.</i> , 109(2):710-12 (February 2002). NPL-191	<input type="checkbox"/>
13	HARRIS, A., et al., "Hypergranulation tissue: a nontraumatic method of management", <i>Ostomy Wound Manage.</i> , 40 (5):20-22, 24, 26-30 (June 1994). NPL-193	<input type="checkbox"/>
14	HARTNETT, S., "Heparin-induced thrombocytopenia as the cause of gluteus muscle necrosis: a case study describing the benefits of multidisciplinary physical and psychosocial interventions", <i>Ostomy Wound Manage.</i> , 47(5):18-26 (May 2001). NPL-194	<input type="checkbox"/>
15	HARTZ, R.R., et al., "Healing of the perineal wound", <i>Arch. Surg.</i> , 115:471-474, (Exhibit D-395) (April 1980). NPL-196	<input type="checkbox"/>
16	HERSH, R.E., et al., "A technique for the treatment of sternal infections using the vacuum assisted closure™ device", <i>Heart Surg. Forum</i> , 4(3):211-15 (2001). NPL-202	<input type="checkbox"/>
17	BIER, A., "Hyperemia by Suction Apparatus" Chapter VIII, pp. 74-85 in "Hyperemia as a therapeutic agent", Chicago, Ill.: Roberts Publishing, (1905). NPL-216	<input type="checkbox"/>
18	IANKOV, N.I., "Stimulation of consolidation of mandibular fractures by means of vacuum therapy", <i>Stomatologiya (Mosk.)</i> , (1 sheet Russian with English abstract, 1 sheet English translation and 1 sheet printout from PubMed); 50 (5):86 (September - October 1971). NPL-217	<input type="checkbox"/>
19	INGBER, D.E., "Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology", <i>Circ. Res.</i> , 91:877-887 (November 15, 2002). NPL-219	<input type="checkbox"/>
20	INOIATOV, I.M., et al., "Vacuum aspiration in the treatment of the perineal wound following extirpation of the rectum", <i>Khirurgiya (Mosk.)</i> , (English abstract on last page, 7 sheets of English translation, 1 sheet printout from PubMed); 47 (1):74-8 (January 1971). NPL-220	<input type="checkbox"/>
21	KALAILIEFF, D., "Vacuum-assisted closure: wound care technology for the new millennium", <i>Perspectives</i> , 22(3) 29-9 (Fall 1998). NPL-230	<input type="checkbox"/>
22	KERCHER, K.W., et al., "Successful salvage of infected PTFE mesh after ventral hernia repair", <i>Ostomy Wound Manage.</i> , 48(10) 40-5 (October 2002). NPL-234	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

23	<p>KIERNAN, M , "The process of granulation and its role in wound healing", Community Nurse, 5(5):47-48 (June 1999). NPL-235</p>	<input type="checkbox"/>
24	<p>KLOTH, L.C., "5 questions-and answers-about negative pressure wound therapy", Adv. Skin Wound Care, 15(5):226, 228-9 (September - October 2002). NPL-237</p>	<input type="checkbox"/>
25	<p>KOCHNEV, V.A., "The use of a vacuum drainage system in the prevention of postoperative wound complications in tumor patients", Vopr. Onkol., (English abstract on last page, 4 sheets of English translation, and 1 sheet printout from PubMed); 13(5):102-5 (1967). NPL-239</p>	<input type="checkbox"/>
26	<p>KOSTIUCHENOK, B.M., et al., "Vacuum treatment in the surgical management of suppurative wounds", Vestn. Khir. Im. I.I. Grek., (English abstract on page 21, 4 sheets English translation, and 1 sheet printout from PubMed); 137(9): 18-21 (September 1986). NPL-241</p>	<input type="checkbox"/>
27	<p>The Kremlin Papers: perspectives in wound care, "A collection of published studies complementing the research and innovation of wound care", 5 articles from the Russian Medical Journal "Vestnik Khirurgii", as translated by BlueSky Publishing, a division of the BlueSky Medical Group Inc. (16 sheets) (2004) (translations of Russian articles dated 1986-1991). NPL-244</p>	<input type="checkbox"/>
28	<p>KUSEL, C., "Use of V.A.C. (vacuum-assisted closure) therapy in general surgery: problem wounds deprived of air", Pflege Z., (and 1 sheet printout from PubMed); 55(6):408-412 (June 2002). NPL-245</p>	<input type="checkbox"/>
29	<p>LABLER, L., et al., "Vacuum sealing of problem wounds", Swiss Surg., (English abstract on first page, 1 sheet printout from PubMed); 8(6):266-7 (2002). NPL-246</p>	<input type="checkbox"/>
30	<p>LEAPER, D.J., "The wound healing process", Advances in Wound Management, T.D. Turner, et al., eds., pp. 7-16, New York: John Wiley and Sons, (1986). NPL-252</p>	<input type="checkbox"/>
31	<p>LETSOU, G.V., et al. "Stimulation of adenylate cyclase activity in cultured endothelial cells subjected to cyclic stretch", J. Cardiovasc. Surg., (September - October 1990) 31(5):634-639; presented at XIX World Congress of International Society for Cardiovascular Surgery (Toronto, Canada, September 5-9, 1989). NPL-253</p>	<input type="checkbox"/>
32	<p>MARSTON, W A , et al., "The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial", Diabetes Care, 26(6) 10 pp., (Exhibit 271) (June 1, 2003) NPL-267</p>	<input type="checkbox"/>
33	<p>Medela Dominant promotional literature (2 pp.) (labeled circa 1984-1985). NPL-274</p>	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

34	Medical Technology & Innovation, "Medical technology is extending life, reducing costs", 1(46), (4 sheets) (December 4, 2000). NPL-275	<input type="checkbox"/>
35	MEEHAN, P.A., "Open abdominal wounds: a creative approach to a challenging problem", Progressions, 4(2):3-8, 11 (1992). NPL-276	<input type="checkbox"/>
36	MENDEZ-EASTMAN, S., "Negative pressure wound therapy", Plast. Surg. Nurs., 18(1):27-29, 33-37 (Spring 1998). NPL-277	<input type="checkbox"/>
37	MENDEZ-EASTMAN, S., "Guidelines for using negative pressure wound therapy", Adv. Skin Wound Care, 14 (6):314-323 and 324-325. (16 pp.) (November - December 2001). NPL-278	<input type="checkbox"/>
38	MENDEZ-EASTMAN, S., "New treatment for an old problem: negative-pressure wound therapy", Nurs., 32(5):58-64. (12 sheets) (May 2002). NPL-279	<input type="checkbox"/>
39	MIRAZIMOV, B.M., et al., "Microflora of prolonged non-healing wounds and the effectiveness of the vacuum evaporative method", Khirurgiia (Mosk.), (English abstract on pages 42-43, 6 sheets English translation, and 1 sheet printout from PubMed); 43(4):40-3 (April 1967). NPL-290	<input type="checkbox"/>
40	MIRAZIMOV, B.M., "Free skin graft of the foot with vacuum preparation of the wound surface", Orthop. Travmatol. Protez., (5 sheets English translation and 1 sheet printout from PubMed); 27(10):19-22 (October 1966). NPL-291	<input type="checkbox"/>
41	MIRAZIMOV, B.M., "Preparation of wounds and ulcers for skin grafting by vacuum treatment", Beitr. Orthop., (and 9 sheets English translation); 14(4):224-30 (1967). NPL-292	<input type="checkbox"/>
42	MIRAZIMOV, B.M., "Free skin grafting of wounds and ulcers using the 'vacuum treatment' method", Orthop. Travmatol. Protez., (7 sheets English translation, and 1 sheet printout from PubMed); 28(1):54-58, (January 1967). NPL-293	<input type="checkbox"/>
43	MIZUNO, K., "Suctioning sponge", Arch. Ophthalmol., 101(2):294 (February 1983). NPL-294	<input type="checkbox"/>
44	MULDER, G. D. et al. (eds.), Clinicians' Pocket Guide to Chronic Wound Repair, 106 pp., second edition (1992). NPL-300	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

45	MULLER, G., "Vacuum dressing in septic wound treatment", Langenbecks Arch. Chir. Suppl. Kongressbd , (English abstract on page 537, and 1 sheet printout from PubMed); 114:537-41 (1997). NPL-301	<input type="checkbox"/>
46	MURRAY, J., et al., "On the local and general influence on the body of increased and diminished atmospheric pressure", Lancet, 1:909-917 (1834-1835). NPL-303	<input type="checkbox"/>
47	MURRAY, Y., "Tradition rather than cure?", Wound Care, Nurs. Times, 84(38):75, 79 and 80 (September 21-27, 1988). NPL-304	<input type="checkbox"/>
48	MUTSCHLER, W. et al., "Temporary skin replacement. An important component in the treatment of skin defects of various etiologies", ZFA , (and 12 sheets of English translation); S. 714-720, pp. 3-15, (1989). NPL-305	<input type="checkbox"/>
49	NETUDYKHATKA, O.I., "Effect of low vacuum on the course of the reparative process in bone tissue", Vopr. Kurortol. Fizioter. Lech. Fiz. Kult., (5 sheets English translation, and 1 sheet printout from PubMed); 37(5):411-5 (September - October 1972). NPL-311	<input type="checkbox"/>
50	NIKOLOV, A., "Vacuum treatment method in postphlebotic and varicose trophic ulcers of the lower extremities", Khirurgia (Sofia), (English abstract on page 371 and 1 sheet printout from PubMed); 34(4):368-371 (1981). NPL-314	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Niels Haun/	Date (YYYY-MM-DD)	2007-05-01
Name/Print	Niels Haun	Registration Number	48,488

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.